首页> 中文期刊> 《四川医学》 >华蟾素联合厄洛替尼抗肺癌A549细胞增殖作用的研究

华蟾素联合厄洛替尼抗肺癌A549细胞增殖作用的研究

         

摘要

Objective To explore the effects of cinobuotalin combined with erlotinib on apoptosis and expression of caspase-3 in lung cancer A549 cell. Methods A549 cells were treated with cinobuotalin,and erlotinib alone or in combination for 48 hours. cell inhibition rate was detected by methylthiazolyl tetrazolium(MTT), the apoptosis rate were determined through Ho-echst33258 staining method and cell cycle were measured by a flow cytometer, and the expression of Caspase-3, were determined by Western Blot. Results The growth inhibition rates and apoptosis rates in the group D were much higher than the group treated by drug alone(P<0. 01). In contrast to each monotherapy group,S stage cell ratio decreased and G0/G1stage cell ratio increased (P<0. 05),in combined treament group D. However the combination of Cinobuotalin and Erlotinib results in down regulation of G 0-G 1 arrest and G 2-M arrest, suggesting that the effect of these two drugs cooperate with each other. The expression of Caspase-3 up-regulated at in the combined treatment group D, and was statistically different from the monotherapy group(P<0. 01). Con-clusion The results suggest that combination treatment with cinobuotalin,and erlotinib can improve therapeutic efficacy against A549 cells,owing to inducing apoptosis 、G 1 phase arrest and up-regulated expressing Caspase-3.%目的:探讨华蟾素联合EGFR抑制剂厄洛替尼对肺腺癌A549细胞株生长抑制和凋亡诱导作用。方法华蟾素、厄洛替尼单独或联合干预细胞48h后,四甲基偶氮唑盐(MTT)比色法测定细胞抑制率;Hoechst33258染色法检测细胞凋亡和流式细胞学检测药物作用周期;Western Blot检测Caspase-3蛋白表达情况。结果①华蟾素联合厄洛替尼组,相比单药组明显抑制A549细胞的生长,呈时间、剂量依赖性;②联合用药组细胞凋亡率明显高于单药组(P<0.01),S期细胞比例明显减少(P<0.01),G0/G1期细胞比例明显增加(P<0.01),表现出协同作用;③联合用药组Caspase-3蛋白表达明显升高(P<0.01)。结论华蟾素和厄洛替尼联合具有协同抑制肺癌细胞生长,其协同作用的可能机制是通过促进凋亡、增强G 0-G 1期阻滞和上调Caspase-3蛋白的表达。

著录项

相似文献

  • 中文文献
  • 外文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号